Literature DB >> 30790104

Management of Atrial Fibrillation in Patients with Heart Failure: Time to Implement Ablation Control.

Alex Baher1, Nassir F Marrouche2.   

Abstract

PURPOSE OF THE REVIEW: Atrial fibrillation (AF) in patients with heart failure and reduced systolic ejection fraction (HFrEF) is common and associated with increased morbidity and mortality, and managing AF in this population has been particularly challenging with sparse data regarding the optimal treatment strategy. RECENT
FINDINGS: Recent data suggests that rhythm control with catheter ablation can be of particular benefit to patients with coexisting AF and HFrEF. Recent randomized control trials actually suggest that catheter ablation could potentially improve mortality in this particular patient population. This is in stark contrast to the current practice recommendations that reserve catheter ablation for symptomatic AF in the general population. In this paper, we will review the most current randomized controlled studies using catheter ablation in HFrEF patients with the hope to increase awareness of the potential mortality benefits the need for prioritization of catheter ablation in HFrEF patients in the next AF management guidelines.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Heart failure with reduced ejection fraction

Mesh:

Year:  2019        PMID: 30790104     DOI: 10.1007/s11886-019-1093-0

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  37 in total

1.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

Authors:  A L Waldo; A J Camm; H deRuyter; P L Friedman; D J MacNeil; J F Pauls; B Pitt; C M Pratt; P J Schwartz; E P Veltri
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

Review 2.  Management of atrial fibrillation.

Authors:  E L Pritchett
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

3.  Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.

Authors:  Michael H Kim; Stephen S Johnston; Bong-Chul Chu; Mehul R Dalal; Kathy L Schulman
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-05-03

4.  Meta-Analysis Comparing Catheter-Guided Ablation Versus Conventional Medical Therapy for Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction.

Authors:  Akram Y Elgendy; Ahmed N Mahmoud; Muhammad S Khan; Maryam R Sheikh; Mohammad K Mojadidi; Mohamed Omer; Islam Y Elgendy; Anthony A Bavry; Kenneth A Ellenbogen; William M Miles; Matthew McKillop
Journal:  Am J Cardiol       Date:  2018-06-05       Impact factor: 2.778

Review 5.  Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials.

Authors:  Chen Chen; Xinbin Zhou; Min Zhu; Shenjie Chen; Jie Chen; Hongwen Cai; Jin Dai; Xiaoming Xu; Wei Mao
Journal:  J Interv Card Electrophysiol       Date:  2018-03-16       Impact factor: 1.900

6.  Rhythm control versus rate control for atrial fibrillation and heart failure.

Authors:  Denis Roy; Mario Talajic; Stanley Nattel; D George Wyse; Paul Dorian; Kerry L Lee; Martial G Bourassa; J Malcolm O Arnold; Alfred E Buxton; A John Camm; Stuart J Connolly; Marc Dubuc; Anique Ducharme; Peter G Guerra; Stefan H Hohnloser; Jean Lambert; Jean-Yves Le Heuzey; Gilles O'Hara; Ole Dyg Pedersen; Jean-Lucien Rouleau; Bramah N Singh; Lynne Warner Stevenson; William G Stevenson; Bernard Thibault; Albert L Waldo
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

7.  Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.

Authors:  Sandeep Prabhu; Andrew J Taylor; Ben T Costello; David M Kaye; Alex J A McLellan; Aleksandr Voskoboinik; Hariharan Sugumar; Siobhan M Lockwood; Michael B Stokes; Bhupesh Pathik; Chrishan J Nalliah; Geoff R Wong; Sonia M Azzopardi; Sarah J Gutman; Geoffrey Lee; Jamie Layland; Justin A Mariani; Liang-Han Ling; Jonathan M Kalman; Peter M Kistler
Journal:  J Am Coll Cardiol       Date:  2017-08-27       Impact factor: 24.094

8.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

9.  Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.

Authors:  G C Flaker; J L Blackshear; R McBride; R A Kronmal; J L Halperin; R G Hart
Journal:  J Am Coll Cardiol       Date:  1992-09       Impact factor: 24.094

10.  [2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS].

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Kardiol Pol       Date:  2016       Impact factor: 3.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.